Literature DB >> 21651616

Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database.

Marine L Andersson1, Linda Björkhem-Bergman, Jonatan D Lindh.   

Abstract

AIM: The aim of the present study was to investigate a previously proposed interaction between quetiapine and lamotrigine resulting in reduced serum quetiapine concentrations.
METHODS: Data on 402 patients subjected to analysis of quetiapine concentration in serum were extracted from a routine therapeutic drug monitoring database. Among these patients, those concomitantly treated with lamotrigine (n= 22) were identified and matched with 22 controls receiving quetiapine while unexposed to lamotrigine. The dose-corrected quetiapine concentrations (C : D ratios) in the two groups were compared in both paired and unpaired analyses.
RESULTS: Patients co-treated with lamotrigine had a lower mean C : D ratio (0.71, 95% CI 0.46, 0.97) compared with controls (1.64, 95% CI 1.00, 2.28). Dose-corrected quetiapine concentrations were 58% lower in patients co-medicated with lamotrigine.
CONCLUSIONS: This study indicates that lamotrigine exposure is associated with substantially reduced serum concentrations of quetiapine, possibly due to induced glucuronidation. These findings need to be confirmed in experimental studies.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651616      PMCID: PMC3141197          DOI: 10.1111/j.1365-2125.2011.03941.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Influence of age and gender on risperidone plasma concentrations.

Authors:  Wolfgang Aichhorn; Ulrike Weiss; Josef Marksteiner; Georg Kemmler; Thomas Walch; Gerald Zernig; Renate Stelzig-Schoeler; Christoph Stuppaeck; Christian Geretsegger
Journal:  J Psychopharmacol       Date:  2005-07       Impact factor: 4.153

2.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.

Authors:  Jagdev Sidhu; Sarah Job; Sunita Singh; Richard Philipson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.

Authors:  A S Eriksson; K Hoppu; A Nergårdh; L Boreus
Journal:  Epilepsia       Date:  1996-08       Impact factor: 5.864

4.  Variation in glucuronidation of lamotrigine in human liver microsomes.

Authors:  U A Argikar; R P Remmel
Journal:  Xenobiotica       Date:  2009-05       Impact factor: 1.908

5.  Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans.

Authors:  A F Cohen; G S Land; D D Breimer; W C Yuen; C Winton; A W Peck
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

6.  Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service.

Authors:  Ingrid Castberg; Eirik Skogvoll; Olav Spigset
Journal:  J Clin Psychiatry       Date:  2007-10       Impact factor: 4.384

7.  Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.

Authors:  Mladena Lalic; Jelena Cvejic; Jovan Popovic; Ksenija Bozic; Svetlana Golocorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

Review 8.  Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.

Authors:  Carlos Figueroa; Martin Brecher; Jennifer E Hamer-Maansson; Helen Winter
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-10-09       Impact factor: 5.067

Review 9.  Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.

Authors:  C L DeVane; C B Nemeroff
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  9 in total
  6 in total

1.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 2.  Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

3.  Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms.

Authors:  Kathryn K Erickson-Ridout; Dongxiao Sun; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

4.  Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011.

Authors:  Simon A Handley; Sally V J Bowskill; Maxine X Patel; Robert J Flanagan
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

Review 5.  Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.

Authors:  Frank M C Besag; Michael J Vasey; Aditya N Sharma; Ivan C H Lam
Journal:  Ther Adv Psychopharmacol       Date:  2021-10-08

6.  Role of Glucuronidation Pathway in Quetiapine Metabolism: An In vivo Drug-Drug Interaction Study between Quetiapine and Probenecid.

Authors:  Haseeb Sattar; Sarmad Sheraz Jadoon; Ni Yang; Shihong Li; Mingzhen Xu; Yong Han; Adil Ramzan; Weiyong Li
Journal:  Saudi J Med Med Sci       Date:  2020-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.